G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs including trilaciclib, a first-in-class therapy designed to improve outcomes for patients treated with chemotherapy. G1 expect to submit an NDA for small cell lung cancer in the second quarter of 2020. The company is also developing rintodestrant, an oral selective estrogen receptor degrader (SERD), and lerociclib, a differentiated oral CDK4/6 inhibitor.